Search Results 2381-2390 of 18878 for Relapse
doi: 10.1016/j.jcmgh.2024.01.006. Epub ahead of print. PMID: 38219900. Phase 1 trial of navitoclax and sorafenib in patients with relapsed ...
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies. Rochester, Minn. The purpose of this study is to find out ...
Studies indicate that ANCA specificity is more important for prognosis, relapse [...] Jan. 08, 2019. Cone-beam CT for enhanced bronchoscopic access to ...
Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or CCUS. Rochester, Minn., Mankato, Minn., La Crosse, Wis ...
Mayo Clinic researchers link CAR-T cell aging to cancer relapse · Tomorrow's Cure: Predicting disease with the power of data · Tomorrow's Cure: The future of ...
NL-201 in Patients With Relapsed or Refractory Cancer. Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to ...
A Study to Evaluate VSV-hIFNbeta-NIS to Treat Patients with Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, or T-cell Lymphoma. Rochester, Minn ...
... relapsed four years later. When Dr. Specks first saw the patient in 1998 he complained of headaches, scalp tenderness, and large-joint pain. He was treated ...
Inotuzumab Ozogamicin In Treating Younger Patients With Relapsed Or Refractory CD22 Positive B Acute Lymphoblastic Leukemia. Rochester, Minn. This phase II ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!